Phase II trial of adjuvant TC (docetaxel/cyclophosphamide) plus trastuzumab in HER2 [human epidermal growth factor receptor 2]-positive early stage breast cancer patients
Phase of Trial: Phase II
Latest Information Update: 05 Nov 2016
At a glance
- Drugs Docetaxel (Primary) ; Cyclophosphamide; Trastuzumab
- Indications Breast cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 05 Nov 2016 Last checked against ClinicalTrials.gov record.
- 20 May 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.